Nuvectis Pharma Announced 33% Response Rate And 100% Disease Control Rate Observed In Patients Evaluated For Efficacy From The NXP800 Phase 1b Clinical Trial In Platinum-Resistant ARID1a-Mutated Ovarian Cancer
Author: Benzinga Newsdesk | March 14, 2024 09:47am